STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
Guidelines for the management of patients with rheumatoid arthritis (RA) envisage that its therapy should be intensified if it is insufficiently effective; at the same time, reduction of its intensity of treatment may be discussed when the set goal has been successfully achieved. The EULAR guideline...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2018-03-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2506 |
| Summary: | Guidelines for the management of patients with rheumatoid arthritis (RA) envisage that its therapy should be intensified if it is insufficiently effective; at the same time, reduction of its intensity of treatment may be discussed when the set goal has been successfully achieved. The EULAR guidelines allow for dose reduction and even discontinuation of biological agents (BAs), especially when performing combination therapy with BAs and disease-modifying antirheumatic drugs (DMARDs). However, the strategy for this therapy change has not yet been sufficiently clearly defined. In this review, we would like to raise an issue regarding frank rather than early RA in patients with irreversible changes of the locomotor apparatus, who have received DMARDs and/or BAs for a long time. When remission is achieved, it is more difficult to reduce the dose of the drug or discontinue the latter in these cases than in early RA. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |